Regulation in China of AI and software in life sciences is still developing in response to rapid tech advances. Will a shift in regulatory focus in China from point-in-time registration to whole-of-life scrutiny impact AI device approval?
The delay gives medical device engineers the chance for a gap analysis and an optimized testing plan, says an expert chemist and toxicologist.